Using Rotenone and Antimycin A
The Two Inhibitors
| Agent | Target | Site | Superoxide mechanism |
|---|---|---|---|
| Rotenone | Complex I | Q-site | Reverse electron transfer at high proton motive force; also from the flavin site |
| Piericidin A | Complex I | Q-site | Same class; more potent |
| Antimycin A | Complex III | Qi site | Qo-site bypass; substantial superoxide production |
| Myxothiazol | Complex III | Qo site | Less superoxide than antimycin |
| TTFA | Complex II | — | Weak; requires high concentrations |
| 3-Nitropropionate | Complex II (SDH) | Irreversible | Requires new enzyme synthesis for recovery |
| Potassium cyanide | Complex IV | — | Highly toxic; fast |
| Oligomycin | ATP synthase | — | Not an ETC inhibitor; hyperpolarises |
Important distinction. Rotenone and antimycin A are the two inhibitors most often used as "specific ETC blocks", and both are among the most potent mitochondrial superoxide generators available. A phenotype that appears with either could be an inhibition phenotype, an oxidative phenotype, or both.
Part 1 — Concentrations and Time
| Agent | Typical in vitro range | Notes |
|---|---|---|
| Rotenone | 0.1–10 µM | Cells concentrate it in mitochondria; effect is fast |
| Antimycin A | 0.1–10 µM | Also fast; superoxide peaks early |
| Oligomycin | 1–2 µM | Titrate; incomplete blockade inflates ATP-linked estimates |
| FCCP | 0.5–2 µM | Titrate; over-uncoupling damages membranes |
Caveat on concentration. Rotenone's cellular potency depends on mitochondrial content and on membrane potential, because uptake is driven by the potential. Cells with more mitochondria reach a higher intramitochondrial concentration at the same medium concentration, which confounds comparisons between lines.
A second caveat concerns partial inhibition: at low concentrations rotenone inhibits reverse electron transfer and superoxide production without substantially reducing forward electron flow. A "low-dose rotenone" experiment may therefore be measuring redox signalling rather than respiration.
Part 2 — Controls That Separate Inhibition from Oxidation
| Control | Purpose |
|---|---|
| Mitochondria-targeted antioxidant (MitoQ, MitoTEMPO) | Tests whether superoxide mediates the phenotype |
| Extracellular antioxidant (NAC, Trolox) | Distinguishes mitochondrial from cytosolic oxidation |
| Substrate-specific respiration in permeabilised cells | Confirms which complex was inhibited |
| Complex II-linked respiration | Should be unaffected by complex I inhibition |
| Viability and ATP measurement | Separates bioenergetic from cytotoxic effects |
| Vehicle (DMSO or ethanol) matched | Both agents are poorly water-soluble |
The first control is the discriminating one. If a mitochondria-targeted antioxidant rescues, the mechanism involves superoxide; if it does not, the mechanism is more likely electron transport itself.
Part 3 — Reversibility and Duration
| Agent | Reversibility | Design consequence |
|---|---|---|
| Rotenone | Slowly reversible; washout incomplete | Short treatments; avoid washout designs |
| Antimycin A | Slowly reversible | Same |
| Oligomycin | Reversible | Washout is feasible |
| FCCP | Rapidly reversible | Washout is feasible |
| 3-Nitropropionate | Irreversible (covalent) | Recovery requires new enzyme |
Caveat on long treatments. Hours of complex inhibition selects for cells with altered mitochondrial content and increased glycolytic capacity. A 48-hour rotenone experiment is partly an adaptation experiment, and the adaptation can dominate the phenotype.
Part 4 — What the Result Supports
| Observation | Supports | Does not support |
|---|---|---|
| OCR falls with rotenone, not with antimycin, in a substrate-specific assay | Complex I dependence of that substrate | General ETC dependence |
| Phenotype rescued by MitoTEMPO | Superoxide-mediated mechanism | Which complex produced it |
| Growth arrest with normal ATP | Biosynthetic limitation | Energy limitation |
| Growth arrest with low ATP | Energy limitation | Which biosynthetic route |
| Resistance after long exposure | Adaptation | A mechanism |
Part 5 — Common Failures
- • A single concentration used as "complex I inhibition".
- • Superoxide production not considered, so an oxidative mechanism is reported as bioenergetic.
- • No mitochondria-targeted antioxidant control.
- • Washout designs used with poorly reversible inhibitors.
- • Long treatments interpreted as acute inhibition.
- • DMSO or ethanol vehicle not matched, at volumes that affect respiration.
- • Oligomycin assumed to give complete ATP synthase blockade.
- • Complex II used as a control without checking that it is unaffected.
Part 6 — Where This Article Connects
This is the inhibitor article of the mitochondrial cluster, and it supplies the acute tools that the respiratory chain article describes genetically. It connects to the OXPHOS-dependency article in the amino acid cluster, where complex inhibition is used to test aspartate supply, and to the Seahorse protocol article, where the same agents are injected.
If you need ETC inhibition tested with antioxidant and substrate-specific controls, we can scope the design with you.
Contact EDITGENE to request a project consultation or quote.
Scientific scope and validation note
Potency, superoxide production and reversibility vary with cell type, mitochondrial content, substrate and concentration. The ranges here are starting points.
Inhibition of a complex does not establish that electron transport was the relevant function, because superoxide production and biosynthetic supply change simultaneously.
Scientific interpretation and experimental design
- • Both inhibitors make superoxide. Control for it.
- • Uptake depends on potential. Concentration is not exposure.
- • Low-dose rotenone is a redox experiment.
- • Washout is limited. Do not design around it.
- • Long exposure selects. It is an adaptation experiment.
- • Titrate oligomycin and uncoupler.
Selected references for further reading
- • Chance B, Williams GR. The respiratory chain and oxidative phosphorylation. Advances in Enzymology. 1956;17:65–134.
- • Murphy MP. How mitochondria produce reactive oxygen species. Biochemical Journal. 2009;417:1–13.
- • Brand MD, Nicholls DG. Assessing mitochondrial dysfunction in cells. Biochemical Journal. 2011;435:297–312.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »